Evidence map›Paper›PMID 26295457›Full record

ArticlePloS one2015

Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion.

Zhen Gong, Jose M Martin-Garcia, Sasha M Daskalova, Felicia M Craciunescu, Lusheng Song, Katerina Dörner, Debra T Hansen, Jay-How Yang, Joshua LaBaer, Brenda G Hogue and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zhen GongDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America.
Jose M Martin-GarciaDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America.
Sasha M DaskalovaDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona 85287-5401, United States of America.
Felicia M CraciunescuCenter for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center of Innovations in Medicine, The Biodesign Institute, Arizona State University, Tempe, Arizona 85287-5901, United States of America.
Lusheng SongVirginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-6401, United States of America.
Katerina DörnerDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America.
Debra T HansenDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center of Innovations in Medicine, The Biodesign Institute, Arizona State University, Tempe, Arizona 85287-5901, United States of America.
Jay-How YangDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America.
Joshua LaBaerDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-6401, United States of America.
Brenda G HogueCenter for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona 85287-5401, United States of America; School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States of America.
Tsafrir S MorCenter for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona 85287-5401, United States of America; School of Life Sciences, Arizona State University, Tempe, AZ 85287-4501, United States of America.
Petra FrommeDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, AZ 85287-1604, United States of America; Center for Applied Structural Discovery, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-1604, United States of America.
Arizona State University · US

Funding

Center for the Rational Design of Membrane Protein CrystallographyU54GM094599 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI FROMME, PETRA · 2010 to 2014
$6.8M
NIGMS NIH HHS U54 GM094599NIGMS NIH HHS U54GM094599
6 · The paper itself

Abstract

The membrane proximal region (MPR, residues 649-683) and transmembrane domain (TMD, residues 684-705) of the gp41 subunit of HIV-1's envelope protein are highly conserved and are important in viral mucosal transmission, virus attachment and membrane fusion with target cells. Several structures of the trimeric membrane proximal external region (residues 662-683) of MPR have been reported at the atomic level; however, the atomic structure of the TMD still remains unknown. To elucidate the structure of both MPR and TMD, we expressed the region spanning both domains, MPR-TM (residues 649-705), in Escherichia coli as a fusion protein with maltose binding protein (MBP). MPR-TM was initially fused to the C-terminus of MBP via a 42 aa-long linker containing a TEV protease recognition site (MBP-linker-MPR-TM). Biophysical characterization indicated that the purified MBP-linker-MPR-TM protein was a monodisperse and stable candidate for crystallization. However, crystals of the MBP-linker-MPR-TM protein could not be obtained in extensive crystallization screens. It is possible that the 42 residue-long linker between MBP and MPR-TM was interfering with crystal formation. To test this hypothesis, the 42 residue-long linker was replaced with three alanine residues. The fusion protein, MBP-AAA-MPR-TM, was similarly purified and characterized. Significantly, both the MBP-linker-MPR-TM and MBP-AAA-MPR-TM proteins strongly interacted with broadly neutralizing monoclonal antibodies 2F5 and 4E10. With epitopes accessible to the broadly neutralizing antibodies, these MBP/MPR-TM recombinant proteins may be in immunologically relevant conformations that mimic a pre-hairpin intermediate of gp41.

Indexed as

AIDS VaccinesCircular DichroismElectrophoresis, Polyacrylamide GelEscherichia coli ProteinsHIV-1HIV Envelope Protein gp41Peptide FragmentsPeriplasmic Binding ProteinsSurface Plasmon ResonanceViral Fusion ProteinsAIDS VaccinesEscherichia coli ProteinsHIV-1 envelope protein gp41 (649-684)HIV Envelope Protein gp41MalE protein, E coliPeptide FragmentsPeriplasmic Binding ProteinsViral Fusion Proteins

Identifiers

PMID26295457
PMCPMC4546420
OpenAlexW1198449314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.